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ABSTRACT 
 
In many developed countries, prostate cancer is the most common male tumor. 
Because of the high incidence and mortality rates, early diagnosis, along with 
prediction of clinical outcome and understanding of the pathogenesis with its 
typical metabolic aberrancies, is awaited with expectation. It is today widely 
accepted that inflammation has a role in many human cancers, including 
prostate cancer. Inflammation is thought to incite carcinogenesis by causing cell 
and genome damage, promoting cellular turnover and creating a tissue 
microenvironment that can foster cell replication, angiogenesis and tissue 
repair. Accordingly, several studies have suggested chronic inflammation of the 
prostate gland may be associated with an increased risk of developing prostate 
cancer. In this work I indicate that, in an inflammatory environment, the human 
prostate gland may synthesize high amounts of estrogens via the local over-
expression of the aromatase enzyme, suggesting that these changes can be 
important in the emergence and/or the progression of prostate cancer. In this 
latter, the expression of key players, such as COX-2 and inflammatory 
cytokines, is significantly altered, favoring cell proliferation and minimizing 
programmed cell death. In addition, estrogens are able to induce amphiregulin 
expression that can, in turn, activate the EGFR signaling, becoming critical for 
the prostate cancer development. Taken together, these data strongly support a 
crucial role of estrogen in the malignant prostate. A better understanding of the 
mechanisms underpinning endocrine, paracrine and autocrine activity of sex 
steroids and their relationship with the inflammatory process in both normal and 
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diseased prostate gland is pivotal to develop new strategies for hormonal 
treatment of human prostatic carcinoma.  
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1. INTRODUCTION 
 
1.1 Epidemiology, risk factors and prevention 
Prostate cancer represents the second most common cancer in men in the 
world and the sixth cause of cancer-related mortality, with 903,500 new cases 
and 258,400 deaths recorded worldwide in 2008 (Figure 1) [1]. The highest 
rates are observed primarily in Northern Europe, North America, and Oceania. 
In Europe, prostate cancer is the commonest type of cancer in men, although 
incidence varies considerably across Northern and Southern Europe, as shown 
in Figure 1[1]. Both genetic and environmental factors may contribute to explain 
this large geographic variation. Studies on populations migrating from countries 
with low incidence/mortality rates (e.g., China or Japan) to countries with higher 
rates of prostate cancer (United States), have revealed, within a generation, a 
significant increase in prostate cancer incidence/mortality as compared with 
their peers in the countries of origin[2-4].  
 
Figure 1. Left: Estimated new cancer cases and deaths worldwide for leading cancer sites; Right: 
the two most common types of new cancer cases. Source: GLOBOCAN 2008. 
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This evidence suggests that lifestyle and dietary factors may play a central role 
in development and progression of human prostate cancer. Several studies 
have hypothesized that plant hormones contained in Asian diets, particularly the 
phytoestrogens present in soy products, might act as natural hormone 
antagonists and anticancer agents and that their intake could be associated 
with a decrease of prostate cancer risk. A recent review [5] of epidemiological 
studies on the association of soy and other nutrients containing phytoestrogens 
with the risk of developing prostate cancer has shown contradictory results, with 
only a few studies reporting a risk reduction associated with the intake of soy 
food, legumes, and isoflavones. In a meta-analysis of 8 epidemiological studies, 
Yan and Spitznagel indicated that the consumption of soy food is related to a 
nearly 30% reduction of prostate cancer risk, despite only 3 studies in the 
analysis showed statistically significant lower risk of prostate cancer [6]. Several 
studies in Asian men have also reported a trend toward a decreased prostate 
cancer risk with increased equol (a gut bacterial product of the 
isoflavonedaidzein) intake. In addition, both lower equol concentrations and a 
lower prevalence of equol-producers have been observed in Asian populations 
among men with prostate cancer as compared with controls, whereas studies in 
European populations have reported no association [7]. 
Several studies have supported the potential role of estrogen role in prostate 
cancer progression, with sex hormones behaving as intermediaries between 
exogenous factors and molecular targets (Figure 2). In this framework, 
endogenous sex steroids, along with genetic factors, environmental factors 
(including diet) host immune and inflammatory responses, are likely to concur in 
the pathogenesis of this disease. [8-11]. 
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Temporal trends in mortality rates of prostate cancer are easier to interpret than 
trends in incidence rates, as they are less or not affected by PSA testing. 
Incidence trends follow in fact a consistent pattern in countries with a 
widespread use of PSA, including Australia, Canada and United States, with a 
rapid rise in incidence in prostate cancer in the early 1990s, soon after the 
introduction of PSA testing, followed by a quick decline [12]. Death rates for 
prostate cancer have been decreasing in many developed countries, including 
Australia, Canada, Finland, France, Israel, Italy, Netherlands, Norway, Portugal, 
Sweden, United Kingdom and United States [12]. In contrast, mortality rates are 
rapidly rising in some Asian and Eastern European countries, such as Japan 
and Poland. While the decrease of prostate cancer death rates in Western 
European and North American countries has been ascribed mainly to earlier 
diagnosis and improved treatment, the increase in Asian and Eastern European 
countries has been thought to be a reflection of “westernization”, including 
Figure 2. Main aspects affecting development and progression of prostate cancer.  
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increased consumption of animal fat, obesity and physical inactivity [13]. Some 
studies suggest that a diet high in processed meat may also be a risk factor 
[14,15] and that risk of dying from prostate cancer is increased in obese [16]. 
Nevertheless, the only well-established risk factors for prostate cancer are older 
age, race (black), and family history [17]. Recent genetic studies suggest that a 
strong familial predisposition may be an important factor to predict an increased 
risk of prostate cancer [18]. Although, modifiable risk factors for prostate cancer 
are not understood well enough to make definitive recommendations for 
preventive measures, factors that may reduce risk include maintaining a healthy 
body weight, getting regular physical activity and consuming a diet low in animal 
fat and high in fruits and vegetables. Evidence on the value of testing for early 
prostate cancer detection is insufficient to recommend for or against screening 
with PSA for men at average risk [19]. The American Cancer Society 
recommends that men who are at average risk of prostate cancer, do not have 
any major medical problems and have a life expectancy of at least 10 years, 
should be informed about the benefits and limitations of testing for early 
prostate cancer detection beginning at age 50 and have an opportunity to make 
an informed decision about testing [20]. 
Treatment options vary depending on age, stage, and grade of the tumor, as 
well as other medical conditions. Surgery, external beam radiation, or 
radioactive seed implants may be used to treat early stage disease. Hormonal 
therapy, chemotherapy and radiation, alone or in combinations, are used for 
metastatic disease and as a supplemental or additional therapy for early stage 
disease. Hormone treatment may control prostate cancer for long periods by 
shrinking the size or limiting the growth of the cancer, thus relieving pain and 
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other symptoms. Careful observation (watchful waiting) rather than immediate 
treatment may be appropriate for some men with less aggressive tumors, 
especially older men with limited life expectancy and/or other health 
considerations. Over the past 25 years, a dramatic improvement in survival has 
been observed, partly attributable to earlier diagnosis of asymptomatic cancers 
and improvements in treatment. The five-year relative survival rate for patients 
diagnosed with prostate cancer in the United States approaches 100% [21] and 
in Europe ranges from 48% (Denmark) to 87% (Austria) [22]. In sub-Saharan 
African and Southeast Asia the five-year survival rate is less than 40% in most 
countries [23].  
 
1.2 Prostate cancer and sex hormones 
1.2.1 Sex steroid metabolism 
Men and women synthesize both androgens and estrogens, but the relative 
ratio of the two hormones between the two sexes is markedly different. The 
importance of androgens to the male is unequivocal, whereas the roles of 
estrogens are less clear. Estrogen synthesis occurs via aromatization of 
androgens through the aromatase enzyme (cytochromeP450arom), with 
aromatase representing a critical regulator of the balance between androgens 
and estrogens and their circulating and tissue levels (Figure 3). In men, the 
balance between plasma levels of androgens and estrogens is significantly 
altered upon aging. Plasma androgen levels decline whereas estradiol levels 
remain relatively constant [24].In specific tissues of the body, the balance 
between androgens and estrogens differ significantly from that in the plasma 
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because it is dependent upon the expression and activity of steroid metabolizing 
enzymes, such as 5α-reductase and aromatase [11,25-27].  
 
 
 
 
The critical role of local synthesis of steroids has assumed increasing 
importance in some disease states, particularly in glandular tissue such as the 
breast, wherein abnormal levels of estradiol may promote either malignant 
transformation or cell proliferation in the early stages of tumor development 
[28,29]. Abnormal expression of aromatase is believed to contribute to the 
development and progression of human breast cancer [28,29]. As there is 
increasing evidence that the prostate is a direct target for estrogenic activity [30-
32], it is important to determine whether or not aromatase is expressed locally 
and to identify any changes that may occur with prostate disease. The Rancho 
Bernardo study, conducted in California, revealed an association of elevated 
plasma estradiol and estrone with an increased risk of prostate cancer [33]. Two 
more recent nested case-control studies on serum levels of both androgens and 
Figure 3. Pathways of sex steroid metabolism in peripheral target tissues. Abbreviations: 
TESTO, testosterone; 4-DIONE, androstenedione; DHT, dihydrotestosterone; 3α-diol, 3α-
androstanediol;3β-diol, 3β-androstanediol; DHEA, dihydroepiandrosterone; 5α-DIOL, 5α-
androstanediol; E2, estradiol; E1, estrone; E2-S, estradiol-sulfate; E1-S,estrone-sulfate. 
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estrogens failed to show any association with prostate cancer risk [34,35]. 
Interestingly enough, one of the two studies has reported a positive association 
of plasma total testosterone with low-grade disease and an inverse association 
with high-grade disease [34].Recently, a limited but significant decrease of 
prostate cancer risk has been associated with increasing serum levels of total 
testosterone [36]. In a study on hypogonadal men, Morgentaler and colleagues 
[37] reported that subjects with PSA levels <4.0 ng/mL had a 15% overall rate 
of prostate biopsies positive for cancer. Interestingly, subjects with plasma 
levels of testosterone <250 ng/dL had a prostate cancer rate of 21%, as 
opposed to 12% for men with a testosterone level >250 ng/dL. Furthermore, the 
probability of cancer in men in the lowest tertile was over twice as much as that 
in men in the highest tertile of both total and free testosterone. Several studies 
have scrutinized the relationship between pretreatment serum levels of 
testosterone with clinical stage of prostate cancer and patient survival, 
suggesting that low serum testosterone could be used as a negative prognostic 
predictor for this neoplasia.  
To date, investigators have raised the question why it has been so difficult to 
demonstrate that plasmatic androgens are associated to an increased risk of 
developing prostate cancer. The most obvious answer to this question is that 
circulating androgens are simply not associated with prostate cancer risk. It 
should be taken into consideration, however, that several issues related to 
measurement of plasma steroids, both androgens and estrogens, could be 
contemplated to explain this large inconsistency of data. They include the low 
statistical strength of most studies, the limited number of incident cases in 
prospective studies, the minor differences in sex steroid serum levels between 
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cases and controls, and the rather large intra- and inter-assay laboratory 
variations of serum hormone measurements [38]. On the other hand, several 
other variables, including obesity, physical activity, diabetes, metabolic 
syndrome and benign prostatic hyperplasia, that might have an impact on 
serum levels of hormones and/or have been related to prostate cancer, have 
not been adjusted for in previous nested case-control studies [39]. 
In any case, it is unlikely that a single assay of plasmatic androgens can be 
regarded as descriptive of average androgen levels over an etiologically 
relevant period of life. In this respect, since the length of prostate 
carcinogenesis and tumor progression can span 35-40 years or longer, the 
timing for the carcinogenetic activity of androgen and/or estrogen on human 
prostate should be counted 20-30 years (or even earlier) prior to the clinical 
manifestation of the disease, when serum androgens are higher and, hence, 
could be biologically relevant. 
So far, aromatase expression in either nontumoral or malignant prostate is 
controversial, with various studies that have detected or failed to detect 
aromatase activity in prostatic tissues [40-43]. 
 
1.2.2 Estrogens in prostate tumor development and progression 
Cellular signaling of estrogens is mediated through two ERs, ERα and ERβ, 
both belonging to the nuclear receptor superfamily of transcription factors. 
Estrogen receptors contain specific and functionally distinct domains. The 
central and most conserved domain, the DNA-binding domain (DBD), is 
involved in DNA recognition and binding, whereas ligand binding occurs in the 
COOH-terminal multifunctional ligand-binding domain (LBD). Transcriptional 
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activation is facilitated by two distinct activation functions (AF), the constitutively 
active AF-1 located at the NH2 terminus of the receptor and the ligand-
dependent AF-2, that resides in the COOH-terminal LBD. Both AF regions 
recruit a range of coregulatory proteins that are bound in complexes to the 
DNA-bound receptor. The two ERs share a high degree of sequence homology 
except in their NH2-terminal domains, and they have similar affinities for 17β-
estradiol (E2) and bind the same DNA response elements (Figure 4).  
 
 
Ligand-dependent estrogen signaling begins with the binding of estrogen to 
ERs. Afterward, the cell-specific transcriptional response to the estrogen 
depends on multiple factors, with the coregulatory complex being fundamental 
to activate estrogen-responsive genes. Since hormones are transcriptional 
modulators, the pattern of regulated genes also depends on other signaling 
pathways that are active in the cell at the time of hormone exposure [44-46].The 
more recent identification of a second ER, the ERβ, and the identification of 
Figure 4. Functional domains of the two major estrogen receptor proteins.  
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several receptor isoforms, has confirmed the complex nature of estrogen 
signaling and helped understanding estrogen activity in tissues that do not 
express ERα. Several splice variants have been described for both receptor 
subtypes (Figure 5), but it remains unclear whether these variants are 
expressed as functional proteins and endowed with biological functions. 
 
 
 
 
 
 
Shorter hERα isoforms lacking exon 1 or exon 1 and 7-8, termed respectively 
hERα46 and hERα36, have been identified both in vivo and vitro [47-50], 
although their role in regulating estrogen effects remains to be determined. 
Functionally, hERα46 lacks the amino-terminal A/B domain present in the full-
length hERα66 and is consequently devoid of the AF1 function. The hERα36, 
consists of a 36 kDa protein variant which lacks both ligand-dependent and-
independent transactivation regions (AF-1 and AF-2), but retains the ligand- and 
DNA-binding domains [48]. Interestingly, both ERα variants have the ability to 
heterodimerize with the full-length hERα, thereby repressing AF-1-mediated 
Figure 5. A) and B) Genomic organization of the human Esr1 and Esr2 gene respectively. The 
location of multiple promoters and corresponding upstream exons of the human ERα gene and 
human ERβ gene are shown left of +1. Upstream exons are represented by numbered boxes and 
their promoters shown as arrows. Downstream Exons are numbered in the corresponding 
blocked region with the nucleotide number above. The  ATG start codon, splice sites and the TAG 
stop codon are also identified. C) and D)  Some mRNAs splice variant of the human ERα and 
human ERβ from hEsr1  and hESR2 gene respectively. 
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activity [47,49]. They may also localize to the plasma membrane, being 
implicated in mechanisms through which rapid, “nongenomic” estrogen 
signaling occurs [49,51]. In particular, ERα36 is expressed both on the plasma 
membrane and in the cytoplasm, where it mediates membrane-initiated effects 
of estrogen signaling, including activation of the mitogen-activated protein 
kinase/extracellular signal-regulated kinase (MAPK/ERK), and stimulation of cell 
proliferation [49]. Today, there is convincing evidence that estrogens may exert 
an amazing array of biological activities through distinct, ER-related pathways 
(Figure 6) [52]. 
 
 
 
 
In fact, other than the classical transcriptional action of E2, rapid effects, that 
occur within seconds or minutes after addition of E2, have been described 
[53,54]. These rapid effects include activation of kinases and phosphatases and 
Figure 6. Major estrogen signaling mechanisms. Adapted from Yager & Davidson, 2006. 
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the increase in ion fluxes across membranes. Also, growth factor signaling may 
eventually lead to activation of kinases that in turn phosphorylate and thereby 
activate ERs and/or recruit coregulators in the absence of ligand [55]. Although 
these rapid effects have been extensively studied, there is still no agreement as 
to whether or not the classical ERs are involved [56,57] or, rather, there is a 
distinct membrane-associated receptor [58]. 
The concept that human prostate cancer represents a paradigm of androgen-
dependent tumor has endured for decades against a bulk of experimental 
evidence suggesting that estrogens and other growth factors may be at least 
equally important in prostate carcinogenesis and tumor progression [10]. The 
expression and functional status of ERs appear to play a significant role in the 
carcinogenesis of all hormone sensitive organs including prostate. 
Recent experimental evidence suggests that prostate cancer originates from 
precancerous lesions, such as chronic proliferative inflammatory atrophy (PIA), 
as a consequence of prostate tissue injury [59]. Normally, in response to tissue 
injury, the prostate stem cell compartment, that represents a minority (1-3%) of 
basal epithelial cells and has been located at the basement membrane of the 
prostatic glandular epithelium, would give rise to a population of transit-
amplifying/intermediate cells that would, in turn, terminally differentiate and 
generate luminal secretory and neuroendocrine epithelial cell types. It is 
speculated that tumor-initiating cells could arise during the prostate 
regeneration process within the pool of prostate stem cells, when their 
differentiation ability is somehow impaired by a mutation activating oncogenic 
and/or abrogating tumor suppressor signaling pathways [60]. The resulting 
progeny of cells would clonally expand and undergo the promotion and 
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progression phases of the multistep carcinogenetic process, eventually leading 
to create a population of cancer stem cells featured by unrestricted replicative 
potential and reduced apoptosis. In this context, estrogens have been reported 
to up-regulate both expression and activity of telomerase in human prostate 
epithelial cell lines, an event that is generally associated with unlimited cell 
proliferation [61]. 
Cavalieri and Rogan [62] have produced consistent experimental evidence in 
support of their hypothesis that selected tissue estrogen metabolites, notably 
the electrophilic catechol estrogen-3,4-quinones, may react with DNA and 
generate depurinating estrogen-DNA adducts. After adducts are released from 
DNA, error-prone base excision repair of the resulting apurinic sites may lead to 
mutations that can be critical to initiate breast, prostate, and several other 
human cancers. 
Some studies have reported that long-term administration of testosterone to rats 
induces the development of prostate tumors, suggesting that testosterone acts 
as a complete carcinogen on the rat prostate, though in a limited proportion of 
cases and in some but not all rat strains [63-65]. However, when Noble rats 
were used as model system, the administration of testosterone and estradiol, in 
sequence or combined, resulted in the occurrence of both ductal and acinar 
epithelial dysplasia, followed within 1 year by the development of 
adenocarcinomas of the dorsolateral prostate in 90-100% of the animals [66]. If 
rats were treated with androgen alone, the incidence of prostate cancer 
dropped to 35-40% [67].  
The mechanisms underpinning the hormonal carcinogenesis in the rat prostate 
remains largely undefined, but there is evidence to suggest that both receptor-
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mediated and nonreceptor effects may be implicated. As far as estrogens are 
concerned, the development of dysplastic lesions in the dorsolateral prostate of 
rats exposed for 16 weeks to a combination of testosterone and estradiol was 
almost completely abrogated by the simultaneous administration of the pure 
antiestrogen ICI-182,780[68]. However, since ICI-182,780 also induces a block 
of the hyperprolactinemia produced in rats by estrogen treatment, it is difficult to 
establish whether the effects of this estrogen antagonist are a consequence of 
binding to estrogen receptor or not. Although most studies on hormonal 
carcinogenesis of the prostate have been conducted on rodents, it ought to be 
emphasized that the rat prostate, consisting of dorsal, lateral, ventral and 
anterior lobes, has embryology and anatomy distinct from human. Therefore, 
results of these studies should be interpreted with caution. 
Both epidemiological and experimental evidence presented herein supports the 
view that prostate cancer arises in the aging male in an estrogenic environment. 
However, the ultimate biological impact of sex steroids, particularly estrogen, on 
prostate cancer cells is difficult to dissect as it is strictly dependent upon several 
variables, including the estrogen:androgen ratio in both plasma and prostate, 
the expression and activity of steroid enzymes, the binding to intracellular 
and/or membrane receptors, the exploitation of genomic and/or nongenomic 
mechanism(s) of action. Previous studies have assessed the proliferative 
effects of sex hormones in cultured prostate cancer cells. Although several 
reports have shown that androgens markedly stimulate prostate cancer cell 
growth [69,70], unequivocal evidence for a direct increase of DNA synthesis 
brought about by bioactive androgens in prostate tumor cell lines is surprisingly 
rare and often conflicting (if any). The inconsistency of the results obtained in 
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cell model systems does not allow to draw any truthful interpretation also 
because different variables, including culture and experimental conditions, age 
of cultured cells, and exposure to endogenous hormones and growth factors 
may considerably affect the results.  
Various in vitro studies carried out on LNCaP cells have indicated that both 
androgen and antiandrogen stimulate growth of these cells [71]. It has been 
previously reported that the exposure to physiological estrogen concentrations 
may either stimulate or decrease growth of androgen-responsive LNCaP and -
refractory PC3 prostate cells, respectively, and that these effects are 
predominantly receptor-mediated, being completely abrogated by the 
simultaneous addition of the pure estrogen antagonist ICI-182,780 [72,73]. This 
evidence implies that estrogen may affect proliferative activity of prostate 
cancer cells even if the cells have become androgen-resistant. This finding is 
also corroborated by the significant rates of clinical response to the systemic 
administration of estrogens observed in prostate cancer patients having a 
metastatic, androgen-refractory disease [74]. Other authors have revealed that 
tamoxifen (a mixed antiestrogen) and ICI-182,780 (a pure antiestrogen) inhibit 
growth of both DU145 and PC3 prostate cancer cell lines and have cytotoxic 
effect on DU145 cells. Based on the finding that the proliferative effects of 
estrogens on human prostate cancer cells in culture appear to be typically 
receptor-mediated, it would be important to assess the ER content and the 
balanced expression of different ER types and their variants in vivo.  
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1.3 The epidermal growth factor receptor axis in prostate cancer 
In the human prostate, epithelium-lined ducts exist in intimate contact with 
smooth muscle cells and undifferentiated fibroblasts of the fibromuscular 
stroma. Moreover, homeostatic interactions between the epithelial compartment 
and the differentiated stromal compartment are believed to be important in the 
maintenance of prostate tissue function in the adult [75]. Stromal-epithelial 
interactions have also been proposed to determine the natural history of tumors 
arising from epithelial organs and descriptive observations of carcinomas 
support the relevance of a stromal-epithelial interaction in tumor progression 
[76-79]. Tumor stroma has been documented to “react” to the presence of 
associated carcinoma cells by altering(usually increasing) the expression levels 
of specific secreted proteins capable of paracrine signaling which have been 
identified as being up-regulated in the reactive stroma [80-82]. 
The epidermal growth factor receptor (EGFR) is a 170-kDatransmembrane 
glycoprotein that has been identified in normal, hyperplastic and malignant 
prostatic epithelium [83-85].Growth factors and their receptors have received 
much attention as potential targets for the treatment of prostate cancer [86,87]. 
Epidermal growth factor (EGF), the related transforming growth factor-α    
(TGFα) and amphiregulin (AREG), are the main autocrine/paracrine growth 
factors that have been identified in prostate cancer specimens and cell lines 
[88-90]. Autocrine activation of EGFR has been proposed as a mechanism to 
support growth and invasiveness of malignant prostate epithelial cells [91-93]. 
The epidermal growth factor receptor is the most extensively studied member 
ofthe ErbB family, which includes ErbB2 (HER-2/Neu) [94], ErbB3 (HER-3) [95], 
and ErbB4 (HER-4) [96]. Many cells co-express multiple ErbB receptors that 
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homodimerize and/or heterodimerize upon stimulation with respective ligands 
[97]. Activated ErbB receptors trigger a number of important intracellular 
signaling pathways, including the phosphoinositide3-kinase (PI3K) and the 
mitogen-activated protein kinase/extracellular-related kinase 1/2 
(MAPK/ERK1/2) pathways. PI3K activity acts as a membrane-associated 
second messenger that binds and recruits a variety of cytosolic signaling 
enzymes to the cell membrane [98]. One of these, the serine/threonine kinase 
Akt, becomes phosphorylated at both Thr308 and Ser473 residues and 
promotes cell survival through multiple mechanisms [99]. The phosphorylation 
status of Akt (P-Akt), in vitro andin vivo, has been widely used to monitor 
aspects of malignant behavior such as proliferation, resistance to 
chemotherapy, irradiation, invasion, and metastasis [100,101].The MAPK 
cascade constitutes a signaling pathway that links surface receptor–mediated 
signals to nuclear events affecting cellular processes of growth, division, 
differentiation, and death [102]. Phosphorylation of the most downstream 
elements, p44 and p42 MAPKs (also called ERK1 andERK2), is a hallmark of 
MAPK activation and is increased in many human tumors, including prostate 
cancer [103,104]. 
Amphiregulin is an epidermal growth factor family member initially purified from 
conditioned media of MCF-7 cells treated with 12-0-tetradecanoylphorbol-13-
acetate [105]. This peptide induces variable effects on growth in different cell 
types. It is an autocrine factor for normal human mammary epithelial cells [106] 
and promotes growth of normal fibroblasts and keratinocytes, as well as some 
ovarian and pituitary tumor cell lines. Amphiregulin has not been shown to 
interact directly with the gene products of other members of the c-erbB family of 
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receptors including c-erbB2, 3, or 4 [107], and thus, the EGFR (c-erb B1/HER1) 
is believed to be the sole cell surface receptor for AREG in epithelial cells [90]. 
Amphiregulin has been reported to be overexpressed in many types of cancers 
including prostate [108],where it is encoded by an estrogen-regulated gene 
[109,110]. It has been suggested that growth factor-based autocrine loops may 
contribute to hormone-refractory tumor growth and that these autocrine 
mechanisms may allow cells to survive after steroid deprivation in human 
prostate cancer cells [111]. 
 
1.4 Inflammation and prostate cancer 
Both Benign Prostate Hyperplasia (BPH) and prostate cancer represent  chronic 
diseases whose development and progression to become clinically manifest 
often requires lengthy time periods[112]. In both these diseases, changes in the 
prostate microenvironment, including growth factors, cytokines and steroid 
hormones, may result in an altered regulation of prostate cell growth consisting 
of elevated cell proliferation and reduced apoptosis [113,114]. 
Inflammation is thought to play a role in the causation of all human cancers. 
Virchow already hypothesized that the origin of cancer is at sites of chronic 
inflammation in 1863 [115]. Several sources of inflammation may influence the 
risk of prostate cancer, including dietary [116], genitourinary bacterial [117,118], 
viral infections[119], and intraprostatic urine reflux [120,121]. With regard to 
diet, a number of nutritional factors may reduce the risk and progression of 
prostate cancer through antioxidant and anti-inflammatory effects (figure 7) 
[116]. These include Ѡ–3 polyunsaturated fatty acids (PUFAs), fish, selenium, 
vitamins D and E, and lycopene [116]. 
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PUFAs are classified according to their molecular configuration: Ѡ–3 or Ѡ–6. 
The pro-inflammatory Ѡ–6PUFAs, such as linoleic acid and arachidonic acid, 
are metabolized through the cyclooxygenase (COX) pathway into inflammatory 
eicosanoids, including prostaglandin E2, which has been linked to 
carcinogenesis in studies of prostate and other tumors [122,123]. In contrast, 
the anti-inflammatory Ѡ–3 PUFAs, such as α -linolenic acid (ALA) 18:3, 
eicosapentaenoic acid (EPA) 20:5, docosahexaenoic acid (DHA) 22:6 and 
docosapentaenoic acid (DPA) 22:5,exhibit their anti-inflammatory properties by 
inhibiting competitively the arachidonic acid cascade, mainly at the COX 
pathway [124]. This inhibition reduces the production of pro-inflammatory 
prostaglandins derived from arachidonic acid, potentially preventing their 
carcinogenic effect. The long-chain Ѡ–3 PUFAs, EPA, DPA and DHA, appear 
Figure 7. Overview of potential pathways linking metabolic disruption to prostate cancer 
progression. Arrows: stimulates/up regulates. Dashed lines: inhibits/down regulates. 
Abbreviations: T2DM, type 2 diabetes mellitus; IGF, insulin-like growth factor; IGFBP, IGF binding 
protein; IL-6, interleukin-6; TNF-α, tumour necrosis factor alpha; VEGF, vascular endothelial 
growth factor.  From Anya J. Burton et al., 2010. 
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to be the most potent inhibitors of the COX inflammatory pathway. Furthermore, 
PUFAs appear to be beneficial in the prevention and treatment of numerous 
disease states, including cardiovascular diseases, neurodegenerative disorders 
and cancer [125]. The role of inflammation in prostatic diseases is suggested by 
the presence of inflammatory cells within the prostate in BPH and prostate 
cancer patients and by the evidence that pro-inflammatory genotypes 
predispose to prostate cancer [126,127,128] (figure 8). Histopathological 
studies have confirmed that inflammation is much more common in the 
transition and peripheral zones of the prostate, where BPH and prostate cancer 
preferentially occur [129,130,131]. Inflammation is a complex phenomenon 
consisting of a humoral (cytokines) and cellular (leukocytes, monocytes and 
macrophages) components [123,132]. Inflammation is usually a self-limited 
event, with an initial release of pro-inflammatory cytokines/growth factors and 
angiogenesis, followed by an anti-inflammatory cytokine–mediated resolution 
[133]. 
In normal tissues, anti-inflammatory cytokines are synchronically upregulated 
after the pro-inflammatory cytokines are produced, leading to inflammation 
resolution, while chronic inflammation, mainly consisting of chronically activated 
T cells and mononuclear phagocytes, is based upon persistence of 
inflammatory stimuli  or a failure in mechanisms required to resolve 
inflammation or both. This condition would result in a further release of 
inflammatory cytokines and various growth factors and attract additional 
immune cells to the inflammation site, thus amplifying the inflammatory 
response [133,134].  
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Stromal–epithelial interaction plays a pivotal regulatory role in the maintenance 
of homeostasis in healthy and diseased prostate [135,136]. In this context, 
Antigen Presenting Cell (APCs)and the expression of the Toll-like receptor 
(TLR) repertoire can produce pro-inflammatory cytokines and activate immune 
responses [130,137,138,139]. Most BPH tissues show a strong expression of 
TLR 4, 5, 7, and 9, whereas an increased expression of TLR 1, 2, and 3 is 
observed in prostate cancer [140]. T-cells, along with prostatic stromal and 
epithelial cells, secrete higher levels of pro-inflammatory cytokines, such as 
interleukins (IL-1, IL-1α, IL-2, IL-4, IL-6, IL-7, IL-8, and IL-17), the CXC-type 
chemokines and their receptors, in BPH and prostate cancer tissues when 
compared to normal prostate tissues [135,137,141]. These cytokines are 
thought to induce fibromuscular reaction and proliferation of prostatic stromal or 
Figure 8. Inflammation in prostate carcinogenesis. Arrows: stimulates. Dashed lines: inhibits. 
Abbreviations: COX-2 cyclooxygenase-2, GSTP glutathione-S-transferase, NF-κB nuclear factor-κB, 
iNOS inducible nitric oxide synthase. From Anya J. Burton et al., 2010. 
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epithelial cell through autocrine or paracrine loops or via induction of COX-2 
expression [130,139,141-143]. IL-1αproduced by epithelial cells induces in turn 
fibroblast growth factor-7 (FGF-7) in prostate stromal cells and this would result 
in benign growth of the prostate. IL-17 up-regulates the secretion of other 
proinflammatory cytokines, such as IL-8 and IL-6 as well as of TGF-β. IL-8 and 
IL-6 are recognized as two potent growth factors for prostatic epithelial and 
stromal cells, with IL-8 playing a major role in stromal proliferation by the 
induction of FGF-2 [126,144]. BPH and prostate cancer show a distinct 
expression of pro-inflammatory cytokines, with elevated IL-6 and IL-8 in cancer 
as compared to BPH tissues [137,140]. In addition, IL-6 regulates prostate 
tumor cell growth and activates androgen receptor-regulated genes in prostate 
cancer cells in the absence of androgen [137].  
Chronic inflammation continuously induces COX-2 [113,115,145,146] and 
COX–2 in turn increases production of prostaglandin (PG) E2, concentrations of 
Bcl-2 protein (the product of a pro-apoptotic gene), and reduces the E-cadherin 
protein(with consequent loss of cell-to-cell adhesion). Overall, COX-2 favors the 
appearance of a malignant phenotype through oxidation of pro-carcinogens to 
carcinogens, increase of cell growth and decrease of apoptosis, reduction of 
immune response and over expression of matrix metalloproteinases with an 
associated increase of invasiveness [126,147-149]. COX-2 is up-regulated in a 
variety of malignancies including prostate cancer [145,150]. COX-2 over 
expression has been reported also in in Prostatic Intraepithelial Neoplasia 
(PIN)and  poorly differentiated tumors [133,140,146,150].  
Chronic inflammation also produces a free radical/oxidative stress, consisting of 
inducible nitricoxide (i-NOS)/reactive nitric species (RNS) and various reactive 
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oxygen species (ROS) [113,115,145,146,151]. This oxidative stress can induce 
vascular damage, protein and genomic alterations, and post-translational 
modifications, including those involved in DNA repair and apoptosis [113]. 
These may eventually lead to a variety of oxidative DNA damage, including 
point mutations, deletions, or chromosomal rearrangements, resulting in 
repetitive cycles of tissue damage and repair, release of cytokines and growth 
factors and an increase of epithelial or stromal cell proliferation 
[133,134,152,153]. Oxidative stress can also activate the transcription factor 
NF-kB (nuclear factor kappa-light chain-enhancer of activated B cells) through 
the TNFα/AP-1transduction pathway and NIK transduction pathway.NF-kB is 
known as a master inflammatory transcriptional regulator and is highly active in 
macrophages. Targets of NFkB include genes regulating immune response, 
inflammation, cell proliferation, cell migration, and apoptosis. The nuclear 
translocation of NF-kB can activate target genes involved in carcinogenesis 
[112,147]. Dysregulation of the transcription factor NF-kB has been proposed as 
one putative molecular mechanism leading to chronic inflammation and 
cancer.TheIL-1β-induced NF-kB pattern of intraprostatic chemoattractive 
signals might have the capability of maintaining the chronic inflammation and 
proliferative inflammatory atrophy (PIA) in the prostate, which are recognized as 
precursor lesions in the development of prostate cancer [154]. 
In the normal prostate, the transduction pathway from NIK/NF-kB seems to be 
inactive. In BPH, there is an increasingly high TNF-α/AP-1 transduction 
pathway, followed by a rise of apoptotic pathways to stop uncontrolled cell 
proliferation. Conversely, in prostate cancer the pro-apoptotic effect of TNF-
α/AP-1 pathway decreases and Is accompanied by an increase of nuclear 
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translocation of NFkB, resulting in the stimulation of prostate tumor cell growth 
[112,134].  
Another distinction between BPH and prostate cancer is gene polymorphism. 
There is consisting evidence that BPH has only rare genetic abnormalities 
[155]. Recently, multiple genes with regulatory roles in inflammatory pathways 
have been associated with prostate cancer risk, including Ribonuclease 
L(RNASEL), macrophage scavenger receptor 1 (MSR1),macrophage inhibitory 
cytokine-1 (MIC-1), interleukins (IL-8, IL-10), vascular endothelial growth 
factor(VEGF) and intercellular adhesion molecule (ICAM),ELAC2/HPC2, 
Machropaghe Scavenger Receptor(SR-A/MSR1), CHEK2, Breast Cancer Gene 
2 (BRCA2), Paraoxonase (PON) 1, 8-oxoguanine glycosylase (OGG-1), TLRs 
and COX-2. Most of these genes are implicated in cellular responses  against 
inflammation andoxidative stress, and defects in their function may be 
associated to an increased risk of developing prostate cancer 
[146,155,156,157-160]. 
An increased production of inflammatory mediators seen visceral fat of the 
obese reflects the ongoing chronic inflammation of the adipose tissue. 
Proinflammatory cytokines are produced by the adipose stroma, as well as by 
the adipocytes (Figures 6 and 7) [161]. Some studies have also found a positive 
association between body mass index and advanced, aggressive and/or fatal 
prostate cancer [162-164]. Adipose tissue produces the enzyme aromatase, 
that presides over conversion of androgens into estrogens. As a consequence, 
obesity is associated with lower total testosterone and higher estrogen levels 
[164-166], which is a challenging concept in the association of prostate cancer 
and obesity. It has been hypothesized that lower androgen concentrations may 
29 
 
provide a microenvironment that favors and selects more aggressive and/or 
androgen-independent tumor cells, indicating one potential mechanism by 
which obesity may influence disease progression [165,166,168].Alternatively, 
lower testosterone levels may represent a bystander effect of the metabolic 
imbalance, which is one basis to prostate carcinogenesis [165], or the 
association between obesity and prostate cancer could be masked by complex 
and inverse relationships with other metabolic hormones such as leptin, insulin 
and IGF-I [169]. However, the intraprostatic conversion of testosterone to  the 
bioactive tissue androgen 5α-dihydrotestosterone may be more influential in 
prostate cancer development than androgens in the circulation [170]. 
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2. PURPOSE OF THE STUDY 
 
 
Despite the recent advances in biotechnology have provided researchers with 
unprecedented potential to attain a deeper understanding of the molecular 
events leading to prostate cancer, this disease continues to be a significant 
healthcare problem world-wide. Prostate cancer remains a major health 
concern for the male population throughout the Western world. Several studies 
have suggested the association of chronic inflammation and prostate cancer, 
whereby prostatic inflammation may be responsible of and/or contribute to 
prostate carcinogenesis and/or tumor progression. Furthermore, high levels of 
endogenous sex steroids are considered as risk factors for prostate cancer. 
Interestingly, it is clear that elevated estrogen in the presence of testosterone 
results in a prostate-specific inflammatory response and that early inflammatory 
events, induced by sex hormones, may serve as a prerequisite for the onset 
of prostate cancer.  
Human prostate cancer is generally considered a prototype of androgen-
dependent tumor; however, estrogen role in both normal and malignant prostate 
appears to be equally important. The association between plasma androgens 
and prostate cancer remains contradictory and mostly not compatible with the 
androgen hypothesis. Apart from methodological problems, a major issue is to 
what extent circulating hormones can be considered representative of their 
intraprostatic levels.  
This thesis is aimed to improve current knowledge on the mechanisms 
underpinning prostate cancer development and progression, with special 
emphasis on sex steroid (notably estrogen) mechanism(s) of action and 
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metabolism in relation to the expression and activity of inflammatory enzymes 
(COX). As the number of men afflicted by prostate cancer will continue to grow 
with the aging population, finding new preventive strategies and innovative 
therapeutic options for this disease is crucial. 
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3. MATERIALS AND METHODS 
 
3.1 Cell cultures treatments 
The RWPE-1 (normal immortalized epithelial prostate cell line, expressing 
androgen receptor), LNCaP (prostate tumor metastasis derived from left 
supraclavicular lymph node, expressing androgen receptor) and PC-3 (prostate 
tumor metastasis of grade IV derived from bone, androgen receptor negative), 
were obtained from the American Type Culture Collection (ATCC, Virginia, 
USA). RWPE-1 cells, were routinely grown and maintained in the Keratinocyte 
Serum Free Medium (K-SFM) base medium added two additives required to 
grow of this cell line, bovine pituitary extract (0.05 mg/ml BPE) and human 
recombinant epidermal growth factor (5 ng/ml EGF), provided by Invitrogen 
(GIBCO, Grand Island, NY). LNCaP and PC-3 cells were routinely grown and 
maintained in RPMI medium containing 10% defined fetal bovine serum 
(Hyclone, Salt Lake City, UT). To all medium was added 1% antibiotic-
antimycotic and 1% L-Glutamine (GIBCO, Grand Island, NY), and all cells were 
grown at temperature of 37°C in an atmosphere of 5%  CO2 and 95% air. 
Subconfluent cell monolayers were rinsed twice in PBS-A (NaCl 170 mM, KC1 
3.4 mM, and Na,PO, 2 mM, pH 7.2), harvested and seeded at a confluence  of 
40%. Cells were left undisturbed for 24 h and then growth for 24h in phenol red-
free RPMI plus 10% charcoal treated-FCS (CT-FCS) and 1 nM 17β-estradiol 
(E2) or 10 µM prostaglandin E2 (PGE2) (Sigma-Aldrich, St. Louis, MO), or 1 nM 
E2 with or without 10 µM of SC-560 (Sigma-Aldrich, St. Louis, MO), a COX1 
specific inhibitor, and/or 10 µM of NS-398 (Sigma-Aldrich, St. Louis, MO), a 
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COX2 specific inhibitor for RT-PCR assay. All cells were grown at temperature 
of 37°C in an atmosphere of 5% CO2 and 95% air. 
 
3.2 Prostate Tissues 
Tissues from benign prostatic hyperplasia (BPH) or prostate cancer (PCa), were 
obtained from patients undergoing surgical resection and/or biopsy procedures. 
Written informed consent was obtained in all cases. Histologically BPH tissues 
were obtained from patients (n = 10; mean age 58 years; range 51-65 years) 
during biopsy procedures. Prostate cancer specimens were obtained from 
patients (n = 10; mean age 53 years; range 48-58 years) during prostate 
surgical resection. All tissue samples were collected immediately after surgery, 
snap frozen in liquid nitrogen and stored at 80°C u ntil analysis. 
 
3.3 RNA extraction, reverse transcription and Polymerase Chain Reaction  
Total RNA were isolated from cells or tissue samples using TRIzol reagent 
according to the manufacturer’s instructions (Invitrogen, Carlsbad, California). 
The extracted amounts of RNA were determined by measuring the absorbance 
at 260 nm, and the RNA integrity was assessed by nondenaturating agarose gel 
electrophoresis. All the RNAs were treated with RNase-free DNase I to remove 
potential contamination of genomic DNA. The cDNAs were synthesized in the 
presence of random hexamer-primer, using SuperScript II reverse transcriptase 
according to the manufacturer’s instructions (Invitrogen, Carlsbad, California). 
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The PCR was conducted with a GeneAmp® PCR System 9700 (Applied 
Biosystems). I used β-actin as internal standard for PCR analysis of estrogen 
receptor alpha 66 (ERα66), estrogen receptor alpha 46 (ERα46), estrogen 
receptor alpha 36 (ERα36), estrogen receptor beta 1 (ERβ1),  estrogen receptor 
beta 2/Cx (ERβ2/Cx), estrogen receptor beta 5 (ERβ5), aromatase (Aro), 
amphiregulin (AREG), ADAM metallopeptidase domain 17, also called tumor 
necrosis factor-α-converting enzyme (TACE/ADAM17), cyclooxygenase-1 
(COX-1), cyclooxygenase-2 (COX-2) and epidermal growth factor 
receptor (EGFR) genes. ERα and ERβ genes were amplified with specific 
primers for exclusive exons of each splice variant. Conventional amplification 
was performed using 35 cycles at 95°C for 30s, spec ific temperature of 
annealing (51-62 °C) for 45s, 72°C for 45s, followe d by 72°C for 5 min 
respectively. The SM-PCR analysis was performed, as previously reported 
(171), a condition whereby PCR products accumulate exponentially and their 
quantity increases in an mRNA-dependent manner. All PCR products were 
analyzed by gel electrophoresis on 2% agarose gels with ethidium bromide 
staining, followed by fluorescence digitization using the software “ImageJ 
1.38X” (National Institutes of Health, USA). Expression level of each transcript 
was quantified relative to β-actin expression level and expressed as arbitrary 
units. Discrete cDNA bands were semiquantitated by digitized evaluation of 
their optical density after subtraction of background. The results were 
expressed as ratios of the intensity of the band of the investigated transcripts to 
the intensity of the band used as internal standard. For semiquantitative 
analysis of the amplified products, a suitable number of PCR cycles for each 
gene and β-actin was determined so that it was within the exponential phase. 
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Exponential regression equations fitted to the curves were used to calculate the 
number of cycles necessary to reach a normalized intensity threshold value = 1 
for each sample. The relative difference in abundance between two samples 
was taken as 2n where n is the difference between the numbers of cycles 
required by the samples to reach the threshold. Three different RNA 
preparations from each experimental condition were pooled to make more 
significant the differences between the expression levels, if any. Oligonucleotide 
primer pairs were designed for human ERα66, ERα46, ERα36, ERβ1, ERβ2/Cx, 
ERβ5, Aro, AREG, TACE/ADAM17, COX-1, COX-2 and EGFR genes, using 
published literature or sequence information contained in the National Center 
for Biotechnology Information GenBank database (see Table 1). 
Oligonucleotide primers were tested using BLAST software to confirm gene 
specificity and to determine exon locations.  
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3.4 Immunocytochemistry 
For immunocytochemistry staining, 1 x 105 of both nontumoral and tumoral 
prostate cell lines were grown directly on slide cover glass. The cover glass was 
removed when the cells covered 80% of the slide. After, the cells were fixed in 
4% formalin for 15 min at 4°C and rinsed twice in 1 × phosphate-buffered saline 
(PBS, pH 7.4) for 5 min each. Endogenous peroxidase activity was removed by 
incubation in 3% hydrogen peroxide and non specific binding was blocked by 
incubation in “NovocastraTM Protein Block” (NovoLinkTM Polymer Kit, 
Novocastra Laboratories, Newcastle, UK) for 5 minutes at room temperature. 
Primary antibodies used included: (a) a mouse anti-hERα (clone F-10) 
monoclonal antibody epitope mapping at the C-terminus of estrogen receptor 
alpha of human origin (dilution 1:50, Santa Cruz Biotechnology, San Diego, 
CA); (b) a goat anti-hERβ (clone L-20) polyclonal antibody directed against a 
peptide mapping near the C-terminus of estrogen receptor beta of human origin 
(dilution 1:50, Santa Cruz Biotechnology, San Diego, CA). The slides were 
incubated with diluted primary antibody for 16h at 4°C. Secondary HRP-
coniugated antibody (NovoLinkTM Polymer Kit) was added to slides for 30 min at 
room temperature and specific staining was identified following incubation with 
a solution of the chromogenic peroxidase substrate, diaminobenzidine 
(DAB)/hydrogen peroxide for 4 minutes. Slides were counterstained with 0.02% 
hematoxylin, followed by successive dehydration in ethanol and xylene before 
mounting of coverslips. Quantitative image analysis was performed using a 
Leica computerized image analysis system with a Qwin software (Leica Imaging 
System Ltd. Cambridge, England). Quantification of immunostaining was 
performed on digitized images representing at least 10 randomly selected fields 
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for each sample. The proportion (%) of positive stain was calculated as the ratio 
of the total area of positively stained cells over the total area of cell nuclei using 
a color discrimination software. 
 
3.5 Androgen and estrogen incubation, steroid extraction and 
chromatographic analysis 
Cell or tissue cultures were washed twice with phosphate-buffered saline 
(PBS)-A and incubated for 24 h in FCS-free phenol red-free RPMI medium 
containing 1 nM tritiated androgen ([1,2,6,7-3H(N)]-testosterone, S.A. 92.4 
Ci/mmol, or [1,2,6,7-3H(N)]-androstenedione, S.A. 84.5 Ci/mmol; DuPont de 
Nemours Italiana SpA, Milan, Italy), or 2 µCi ml-1 tritiated estrogen ([6,7-3H(N)]-
E2) as precursor. For cultured cells, following incubation medium was 
transferred to plastic tubes and stored at −80 ◦C until analysis. As far as tissue 
cultures are concerned, minced tissues were resuspended in the incubation 
medium, transferred to a plastic tube and centrifuged at 2000 rpm for 5 minutes. 
The resulting pellet was gently homogenized using a glass-glass 
Douncehomogenizer (Kontes Co., Vineland, NJ) in 3ml of PBS, while the 
supernatant (incubation medium) was transferred to a separate tube. Both the 
homogenate and the medium were stored at −80 ◦C until steroid extraction. 
Medium and cells were therefore processed as described below. 
Steroid extraction was carried out on the incubation medium, since we have 
previously shown it contains proportionally greater amounts of radioactive 
steroids than those found in both cell and tissue homogenates. Extraction of 
steroids was performed with SPE method in Vac-Elut apparatus using C18 
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cartridges on 1ml aliquots of medium. Briefly, two fractions were collected: in 
the first, conjugate (sulfate and glucuronide) steroids were eluted using water–
methanol solution (60:40, v/v); in the second, the free (unbound) steroids were 
eluted using water–methanol solution (15:85, v/v). The two fractions were dried 
in a SVC100H Speed Vac evaporator-concentrator (Savant Instruments Inc, 
Farmigdale, NY) and conjugate steroids were hydrolized at 37 °C for 18 h, in 
1ml of a solution consisting of 970 µl of 0.2M acetate buffer (pH 5.0) and 30 µl 
of Glusulase enzyme mixture (duPont Co, Wilmingon, DE). The hydrolyzed 
steroids were extracted again with SPE method using ethylacetate and 
evaporated to dryness, as described above. Both free and conjugate steroids 
were analyzed in RP-HPLC using a Beckman 324 model HPLC system 
equipped with an UV detector set at 280 nm, and an on line Flo-One/beta 
(500TR Series) three-channelflow scintillation analyzer (Packard Instrument Co, 
Meriden, CT). Steroids were eluted under isocratic conditions using a 
Ultrasphere ODS column (250×4.6 I.D.mm) and an optimized mobile phase 
consisting of acetonitrile: tetrahydrofuran: 0.05 M citric acid (39: 6: 55, v/v/v) at 
a flow rate of 1ml/min. Radiometric detection was performed using a 1 ml flow 
cell and Ultima-Flo-M (Camberra-Packard) scintillation mixture at flow rate of 
4ml/min. Routine data integration was achieved by the Flo-One radio-HPLC 
workstation software package (Packard) and computed in net cpm, after 
correction for both residence time and background subtraction. 
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3.6 Cell proliferation assay 
The MTS assay (CellTiter 96® AQueous One Solution Cell Proliferation Assay, 
Promega Corporation, Madison, USA) was used to measure cell proliferation or 
viability in cultures. Cells were seeded at a confluence of 30% in 96-well 
microplates and then growth for 24h in phenol red-free RPMI plus 10% charcoal 
treated-FCS (CT-FCS) and 1 nM 17β-estradiol (E2) or 10 µM prostaglandin E2 
(PGE2), or 1 nM E2 with or without 10 µg/ml of genistein or resveratrol (Sigma-
Aldrich, St. Louis, MO), or 1 nM E2 with or without 2 µg/ml of amphiregulin 
antibody (R&D Systems, Minneapolis, USA),  or 50 nM of amphiregulin protein 
(Sigma-Aldrich, St. Louis, MO). In brief, the MTS tetrazolium compound 
(Owen’s reagent) is bioreduced by cells into a colored formazan product that is 
soluble in tissue culture medium. This conversion is presumably accomplished 
by NADPH or NADH produced by dehydrogenase enzymes in metabolically 
active cells. Assays are performed by adding a small amount of the CellTiter 
96® AQueous One Solution Reagent directly to culture wells, incubating for 1–4 
hours and then recording the absorbance at 490nm with a 96-well plate reader. 
The quantity of formazan product as measured by the absorbance at 490nm is 
directly proportional to the number of living cells in culture. All cells were grown 
at temperature of 37°C in an atmosphere of 5% CO2 a nd 95% air. Control cells 
received vehicle (0.1% ethanol) only and all experiments were performed in 
triplicates. Cell having a narrow range of passage number were used for all 
experiments. 
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3.7 Cell differentiation  
Growth factor-reduced Matrigel (BD Biosciences, San Jose) was placed in the 
well of a pre-chilled 6-well cell culture plate and incubated at 37°C for 1 hr to 
allow polymerization. RWPE-1, LNCaP and PC-3 cells, at concentrations of 
4×104 per well, were plated into the growth factor-reduced Matrigel coated 
wells, and incubated at 37°C in 5% CO2 in the condi tioned media with or 
without 1 nM 17β-estradiol (E2). After 48-72 h incubation, the plates were 
photographed. Tube formation was quantified by counting the number of 
connected cells in five randomly selected fields at ×200 magnification. All 
experiments were performed in triplicates.  
 
3.8 Statistics 
The data were expressed as mean ± SD. Analyses were performed using 
computerized statistical software with the ANOVA test. When ANOVA revealed 
P<0,05 the data were further analyzed by Dunnet’s t-tests. Differences were 
considered statistically significant at P < 0,05. 
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4. RESULTS 
 
4.1 Expression of ERα and ERβ wild-type and splicing variants in 
nontumoral and malignant human prostate cell lines 
 
The expression of ERα and ERβ mRNA, was investigated using an exon-
specific RT-PCR analysis on a panel of nontumoral (RWPE-1) and malignant 
(LNCaP and PC-3) prostate epithelial cell lines. 
 
 
 
 
In particular, ERα mRNA expression was inspected using RT-PCR with primer 
sequences located within regions A/B (exon 1) and D (exon 4) for ERα66 (wild-
type mRNA), within promoter F and region C (exon 2) for ERα46mRNA and 
within region C (exon 2) and an additional region (exon 9) for ERα36 mRNA. 
Using ERα66-specific primers, the PCR product was revealed only in RWPE-1, 
while no ERα66 could be detected in LNCaP and PC-3 cell lines. ERα46 was 
Figure 9. Expression of ERα and ERβ wild-type and splicing variants mRNA in nontumoral 
(RWPE-1) and malignant (LNCaP and PC-3) prostate epithelial cell lines. 
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expressed both RWPE-1 and LNCaP, but not in PC3. Interestingly, ERα36 
appeared to be inversely related to ERα66 expression, with very low levels in 
RWPE-1 cell line, intermediate levels in LNCaP cells, and high levels in PC-3 
cells. ERβ mRNA expression was inspected using RT-PCR with primer 
sequences located within exon 7 and exon 8 for ERβ1 (wild-type mRNA), 
within exon 7 and an additional region exon Cx for ERβ2/Cx mRNA, within 
exon 7 and an additional region exon β5 for ERβ5 mRNA. The expression 
pattern of ERβ isoforms is rather variable, with ERβ5 being not expressed in 
RWPE-1 cells only, while PC-3 cells express high levels of all ERβ isoforms 
(Figure 9). The expression of ERα and ERβ isoforms was also determined at 
protein level using immunocytochemistry assay (ICA) on cells grown directly on 
glass slides. Overall, data of ICA were largely in accordance to what observed 
using RT-PCR analysis. In particular, using an antibody directed against a C-
terminus epitope of ERα, shared by both ERα66 and ERα46 protein, but 
absent in ERα36 protein, ERα66 was detected in both RWPE-1 and LNCaP 
cells, while no ERα66 protein could be revealed in PC-3 cells. ERβ protein was 
expressed ubiquitously in all the cell lines tested (Figure 10).  
 
Figure 10. Expression of ERα and ERβ protein in nontumoral (RWPE-1) and malignant (LNCaP 
and PC-3) prostate epithelial cell lines. 
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4.2 Expression of aromatase, amphiregulin, TACE/ADAM17 and COX 1/2 
in nontumoral and malignant human prostate cell lines 
The expression of aromatase (Aro), amphiregulin (AREG), TACE/ADAM17, 
COX1 and COX2, was investigated using RT-PCR analysis in RWPE-1, 
LNCaP and PC-3 prostate epithelial cell lines. Aro expression levels 
corresponded to those of chromatographic analysis of aromatase activity, 
being very low or undetectable in all cell lines tested. AREG was detected only 
in PC-3 cells, while TACE/ADAM17 and COX1 were ubiquitously present in all 
cell lines. No COX 2 could be detected in LNCaP cells (figure 11). 
 
 
 
 
 
Figure 11. Expression of Aro, AREG, TACE, COX1 and COX2 mRNA in nontumoral (RWPE-1) and 
malignant (LNCaP and PC-3) prostate epithelial cell lines. 
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4.3 Effects of estradiol and prostaglandin E2 on the expression of Aro, 
AREG, TACE/ADAM17 and COX1/2 in nontumoral and malignant 
human prostate cell lines 
The potential effect of both E2 and PGE2 on the expression of Aro, AREG, 
TACE/ADAM17, COX1 and COX2 genes was scrutinized in RWPE-1, LNCaP 
and PC-3 prostate epithelial cell lines. Treatment of cells with 1 nM E2 resulted 
in the up-regulation of all genes tested except COX-1. In particular, Aro and 
AREG mRNA were induced 3,2 fold and 5,1 fold respectively in PC-3cells. 
Interestingly, E2 induced aromatase expression also in Aro-negative LNCaP 
cells, suggesting that transcriptional activity of this gene remains potentially 
inducible. After E2 treatment, TACE/ADAM17 mRNA was 1,9 fold, 2,3 fold and 
2,7 fold greater than in control in RWPE-1, LNCaP and PC-3 cells, 
respectively. COX-2 expression was up-regulated as well by E2, with 
expression levels 2,5 fold and 2,9 fold higher than in control in RWPE-1 
andPC-3 cells, respectively (figure 12).  
 
Figure 12. Expression of Aro, AREG, TACE, COX-1 and COX-2 mRNA after 1 nM estradiol (E2) 
treatment in nontumoral (RWPE-1) and malignant (LNCaP and PC-3) prostate epithelial cell lines. 
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Interestingly, also PGE2 was able to induce Aro expression in both PC-3 cells 
(3-fold) and Aro-negative LNCaP cells (Figure 13). 
 
 
In addition, the use of specific COX-1/2 inhibitor (SC-560, a COX-1 inhibitor 
and NS-398, a COX-2 inhibitor),resulted in a decrease or in the abrogation of 
the E2-induced Aro expression in LNCaP and PC3 cells, suggesting that both 
COX1/2-dependent and -independent effects of SC-560 and NS-398 could be 
implicated in the regulation of Aro expression in human epithelial prostate 
cancer cells (Figure 14). 
 
 
Figure 13. Expression of Aro after 10 µM prostaglandin E2 (PGE2) treatment in nontumoral 
(RWPE-1) and malignant (LNCaP and PC-3) prostate epithelial cell lines. 
 
Figure 14. Expression of Aro after 1 nM estradiol (E2) treatment, with or without 10 µM SC-560 
or NS-398, in LNCaP and PC-3 prostate cancer cell lines. 
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Lastly, aiming to evaluate the potential role of E2 on EGFR-axis in PC-3 cells, 
this cell line was treated with 1 nM E2 or 10 µM PGE2, and the potential 
effects on AREG, TACE/ADAM17 and EGFR expression were evaluated. PC-3 
cells express significant amounts of epidermal growth factor receptor; E2 
induced both AREG (5.1-fold) and TACE (2.7-fold), suggesting that estrogen is 
potentially able to trigger EGFR through the activation of expression/function of 
AREG (Figure 15).  
 
 
 
 
 
 
 
 
 
 
Figure 15. Expression of AREG, TACE and EGFR with or without 1 nM of estradiol (E2) treatment 
or 10 µM PGE2 treatment in PC-3 prostate cancer cell line. 
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4.4 Androgen and estrogen metabolism in nontumoral and malignant 
human prostate cell lines 
 
Overall, data from in vitro studies reveal that activities of steroid enzymes, 
including aromatase, sulfotransferase, sulfatase, glucuronil-transferase, 17β-
HSDand 5α-reductases, are markedly divergent in nontumoral (RWPE-1) and 
malignant (LNCaP and PC-3) human prostate epithelial cell lines. Results of 
24h incubation of cells with either testosterone (T) or estradiol (E2) as androgen 
or estrogen precursor, are reported in Figure 16. In the first place, only PC-3 
cell line shows a remarkable androgen metabolism, with on average only 1.9% 
testosterone remaining unconverted after incubation. By contrast, after 24h 
incubation with T in RWPE-1 and LNCaP cells, only a limited androgen 
metabolism was observed, with an average of 92% and 93% T remaining 
unconverted after incubation, respectively. This different metabolic aptitude is 
reflected in the prevalence of reductive metabolism in RWPE-1 and LNCaP 
androgen-responsive cells, while oxidative pathways are largely dominant in 
PC3 androgen-refractory cells. Also, only RWPE-1 produced quantifiable 
amounts (around 4,7%) of the biologically active androgen DHT and only PC-3 
cell line showed a significant 5α-reductase activity, accounting on average for 
28% of all androgen metabolites. Aromatase activity could not be detected in 
any of the cell lines tested. Interestingly, RWPE-1 cells, incubated for 24h with 
E2, gave rise to 75% estradiol-sulfate formation, while PC-3 cells produced 
33,5% estrone (E1), 8% estradiol sulfate and 27% estrone sulfate. No E2 
metabolism was observed in LNCaP cells showing instead a massive (97%) 
activity of the glucuronil-transferase enzyme when incubated with T (Figure 16). 
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4.5 Androgen and estrogen metabolism in benign prostatic hyperplasia 
and prostate cancer tissues 
 
Patterns of androgen metabolism were also investigated in minced prostate 
tissue samples, under exactly the same experimental conditions used for in vitro 
studies. These studies were conducted on a series of hyperplasic (BPH) and 
malignant human prostate tissues. As reported in Figure 17, both BPH and 
cancer tissues exhibited a significant proportion of T conversion into 
dihydrotestosterone (DHT) and 3α/3β-diols (biologically active androgen 
metabolites), with an average of 69% and 89% respectively. Overall, the 
formation of 5α-androstanedione (5αAd) and androsterone (A) was limited to 
20% and 5% in BPH and cancer, respectively (Figure 17). Both BPH and 
prostate cancer specimens did not exhibit detectable amounts of estrogen 
and/or intermediate products of the aromatase enzyme (data not shown). 
Figure 16. Androgen an Estrogen metabolism in nontumoral (RWPE-1) and malignant (LNCaP and 
PC-3) prostate epithelial cell lines after 24 h incubation with 1 nM tritiated testosterone (T) and 1 
nM tritiated estradiol (E2). Data represent mean ±SD values of conversion rates (% conversion) 
from triplicate experiments. 
49 
 
 
 
 
 
Interestingly, when androgen metabolism was investigated in separate epithelial 
and stromal cell of BPH, aromatase activity was present in stromal cells only, 
with a 3.6% E1 production (data not shown). In addition, results obtained in 
from primary cultures of stromal and epithelial cells from BPH tissues revealed 
a prevalent oxidative androgen metabolism, leading to the formation of 17keto 
androgen metabolites in either cell type (Figure 18). 
 
 
 
Figure 17. Androgen metabolism in hyperplasic (BPH) and malignant (PCa) human prostate 
tissues after 24h incubation with 1 nM tritiated testosterone (T).Data represent mean ±SD values 
of conversion rates (% conversion) from triplicate experiments. 
Figure 18. Androgen metabolism in BPH tissue vs primary cultures of stromal and ephitelial cells 
derived from BPH. BPH tissues and their epithelial and stromal cells were incubated for 24h with 1 
nM tritiated testosterone (T). Data represent mean ±SD values of conversion rates (% conversion) 
from triplicate experiments. 
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4.6 Growth effects of estradiol, Genistein and Resveratrol on nontumoral 
and malignant human prostate cell lines 
 
To establish the effect of estradiol, genistein and resveratrol on cell proliferation 
of epithelial prostate cells with different ER status, a series of experiments were 
conducted on RWPE-1, LNCaP and PC3 prostate epithelial cell lines. RWPE-1 
cells, which express all the ERα and ERβ splice variants except ERβ5, 
displayed a significant induction of growth with E2 (78%), with E2 plus genistein 
(25%) and E2 plus resveratrol (51%). Resveratrol alone induced a nearly  20% 
growth increase in RWPE-1 cells, while genistein and genistein plus resveratrol 
inhibited growth of RWPE-1 cells respectively by 18% and 17%. A 
corresponding figure was observed in LNCaP cells, that express all ERα and 
ERβ splice variants except ERα66 (E2=+37%; E2 and genistein=+3%; E2 and 
resveratrol=+21%; resveratrol=+18%; genistein and resveratrol=-49%), while all 
treatment inhibit cell proliferation in PC-3 cells, expressing only ERα36 mRNA 
and all ERβ splice variant mRNA tested (E2=-15%; genistein=-42%; 
resveratrol=-52%; E2 and genistein=-23%; E2 and resveratrol=-4%; genistein 
and resveratrol=-58%). These effects were observed after 24h exposure to  
concentrations of 1nM estradiol, 10 µg/mlgenistein and 10 µg/ml resveratrol 
(Figure 19). 
 
4.7 Growth effects of estradiol, AREG and PGE2 on nontumoral and 
malignant human prostate cell lines 
Measurement of cell proliferation showed that growth of RWPE-1 cells was 
stimulated by 1 nM E2 (65%), while non significant proliferative effects were 
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observed after exposure to AREG (50 nM) and PGE2 (10 µM) slightly induced 
cell proliferation (17%). 
 
 
 
E2 increased cell growth also in LNCaP cells and this effect could be abrogated 
by the addition of a neutralizing antibody (2 µg/ml) directed against AREG. A 
comparable effect was observed when LNCaP cells were treated with AREG 
along with an anti-AREG antibody, while AREG alone induced a 30% increase 
of LNCaP cell growth. On the contrary, PGE2 induced LNCaP cell proliferation 
only limitedly (8%). Lastly, PC-3 cells, that express high levels of EGFR, 
showed an increase (63%) of their proliferative activity in response to AREG. 
Once again, this effect could be abolished after addition of neutralizing antibody 
anti-AREG. In this cell line, PGE2 induced a significant increase of cell 
proliferation (43%) (Figure 20). 
Figure 19. Effect of estradiol (1 nM), genistein (10 µg/ml) and resveratrol (10 µg/ml) on cell 
proliferation of  nontumoral  (RWPE-1) and tumoral (LNCaP and PC3) epithelial prostate cell lines. 
All experiments were conducted in triplicate. 
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4.8 Effects of estradiol on differentiation of nontumoral and malignant 
human prostate cell lines  
The potential of E2 to sustain glandular (acini) formation of nontumoral (RWPE-
1) and malignant (LNCaP and PC-3) prostate epithelial cell lines was assessed 
in a differentiating environment (Matrigel). This condition, normally, induce cell 
lines to self-organize in athree-dimensional tubular network wherein cells are 
arranged in aduct-like pattern around a central space (differentiation process). 
Significant differences were observed in the patterns of duct-like structures of 
the three cell lines after 2-3 days in culture. Interestingly enough, only RWPE-1 
after E2 showed the formation of “branching end buds” or “ductular-alveolar 
outgrowths”, while neither control (untreated) RWPE-1 cells, nor the other two 
cells lines (LNCaP, PC-3 cells), under any condition, produced this kind of 
three-dimensional process. Treatment with 1 nM E2 increased growth in LNCaP 
and PC-3 cells, but failed to induce any differentiation, independent of the 
Figure 20. Effect of estradiol (1 nM), amphiregulin protein (50 nM) prostaglandin E2 (10 µM) 
genistein (10 µg/ml) and amphiregulin antibody (2 µg/ml) on cell proliferation of  nontumoral  
(RWPE-1) and malignant (LNCaP and PC3) epithelial prostate cell lines. All experiments were 
conducted in triplicate. 
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presence or absence of E2 (Figure 21). To better dissect the E2 role in the 
regulation of ductal-alveolar morphogenesis, no sera and only phenol red-free 
media were used. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. Effect of 1 nM estradiol (E2) on differentiation of nontumoral  (RWPE-1) and malignant 
(LNCaP and PC3) epithelial prostate cell lines. 
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5. DISCUSSION 
While androgens have been historically considered male hormones and the 
sole responsible for both normal and malignant prostate growth, sex steroids 
exert similar, yet different, effects in the prostate, and it is becoming clear that a 
finely tuned balance between estrogen effects mediated by ERα and ERβ, is 
required for the maintenance of prostate health. The action of estrogens is 
complex, having both adverse and beneficial roles via ERα and ERβ 
respectively. The present study indicates that estradiol is an important factor to 
induce differentiation only in nontumoral RWPE-1 prostate cells, while estradiol 
regulates cell proliferation in LNCaP and PC3 prostate cancer cells. The 
adverse effects, namely malignant transformation, aberrant cell proliferation, 
and chronic inflammation, all seemingly require the presence and activity of 
ERα, providing a rationale for the use of ERα-specific antagonists in the 
chemoprevention of human prostate cancer. Conversely, ERβ appears to 
promote beneficial effects by antagonizing the carcinogenetic process and 
preventing the development of hyperplastic lesions and inflammatory response, 
thus providing the rationale for the use of ERβ agonists as a therapeutic option 
for both BPH and prostate cancer [172]. Although the beneficial effects of 
modulating estrogen receptor activity as a target for treatment of prostate 
diseases have been demonstrated by several studies in vitro and in animal 
model systems, the translation of this information into potential therapeutic 
applications, particularly for prostate cancer, is likely to be highly challenging. 
This complication lies in a number of factors. In the first place, ERβ expression 
is variable and appears to be down-regulated or even silenced during prostate 
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cancer progression. In addition, little is known about the expression and/or 
function of the ER splice variants, gene mutations, ligand-dependent and 
independent receptor activation and the role of genomic versus non-genomic 
signaling in various target tissues and cells [49,56,173,174]. Despite this 
complexity, there is significant potential for the use of targeted ER therapies in 
prostate diseases and this clearly warrants further investigation. 
Overall, the potential role played by estrogens in the neoplastic transformation 
of prostate epithelial cells, as well as in prostate cancer progression remains 
controversial. Exposure of humans or rodents to estrogens generally induces a 
proliferative lesion, called squamous metaplasia, in their prostates [175-177], 
whereas prolonged treatment of rats with androgen plus estrogen causes a high 
incidence of prostate cancer lesions in the dorsolateral prostates of the treated 
animals [178-180]. Paradoxically, diethylstilbestrol, tamoxifen, and other 
estrogenic drugs have been used as treatment for advanced, metastatic 
prostate cancer [181-186]. Other than acting as chemical castration agents, 
both estrogens and antiestrogens are believed to exert direct growth-inhibitory 
effects on prostatic cancer cells via the induction of apoptosis or cell cycle 
arrest [187-190]. Precisely how estrogens/antiestrogens elicit these actions 
remains uncertain. Traditionally, the activities of estrogens/antiestrogens are 
thought to be mediated via the classical pathways, namely by binding to ER 
localized in the stromal compartment and basal epithelial cells of human and 
rodent prostates [191-194]. Because ERα is not expressed in the normal 
glandular epithelium of rat or human prostate [188,192-194], it is generally 
believed that the effects of estrogen/antiestrogen on normal prostate epithelial 
cells are indirect, presumably mediated via estrogen-induced stromal factors. 
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Results of the present study reveal that amphiregulin (AREG), a EGF-like 
growth factor, is expressed and induced by both E2 and PGE2 in PC3 cell line. 
In addition, E2 is also able to induce TACE/ADAM17 (a transmembrane 
proteolytic enzyme that produces the bioactive forms of AREG) in RWPE-1, 
LNCaP and PC3 cells. In this respect, AREG may be considered an estrogen-
regulated factor that could mediate estrogen stimulation of cell proliferation via 
the activation of EGFR signaling.   
After the discovery of ERβ [195] and its localization to the epithelial 
compartment of rodent prostates [196], a distinct possibility has been raised that 
estrogen/antiestrogen could affect prostate epithelial cells function via an ERβ 
signaling pathway. Although some author [192] has evaluated the expression of  
ERβ transcripts and proteins in human prostate and found undetectable levels 
in both normal and diseased tissues, this study unequivocally demonstrates the  
expression of wild-type ERβ and its splicing variants ERβ2/Cx and ERβ5 in 
nontumoral RWPE-1 and malignant LNCaP and PC3 epithelial prostate cells. 
Several investigators have detected ERα expression in human prostate cancer 
cell lines, including LNCaP, PC-3, and DU-145 cells  [72,73], whereas others  
did not [197]. Reports on ERα expression in prostate cancer specimens were 
equally controversial. Bonkhoff et al. [192] reported that ERα expression was 
infrequent in low-to-moderate grade prostatic adenocarcinomas, but common in 
high-grade and metastatic cancers. Conversely, Konishi et al. [198] revealed 
ERα immunopositivity in well-differentiated adenocarcinomas, but not in poorly 
differentiated prostate tumors. This issue becomes even more intricate when 
the expression pattern of ERβ is taken into consideration. Additionally, several 
variants of ERα are often found to coexist with the wild-type transcript in normal 
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and malignant prostate tissues [50]. These variants, produced by alternative 
splicing, are whole exon variants that may have “outlaw functions”. In the 
current study, wild-type ERα66 was expressed only in RWPE-1, while no 
ERα66 could be detected in LNCaP and PC-3 cell lines. ERα46 was expressed 
both RWPE-1 and LNCaP, while no expression was observed in PC3 cells. 
Intriguingly, ERα36 appeared to be inversely related to ERα66 expression, with 
very low levels in nontumoral RWPE-1 cells, intermediate levels in hormone-
responsive LNCaP cells and high levels in androgen-refractory PC-3 cancer 
cells. The expression pattern of ERβ isoforms was rather variable with RWPE-1 
cells only expressing no ERβ5 and PC-3 expressing high levels of all ERβ 
isoforms studied. This complex framework implies that, to understand the role  
played by ER-mediated signaling in prostate carcinogenesis, an accurate 
assessment of both wild-type and variants ERs should be conducted comparing  
normal and cancerous prostate gland. As a matter of fact, this study clearly 
indicates that diverse ER ligands can have distinct effects on the proliferative 
activity of prostate epithelial cells. Estradiol alone and estradiol plus genistein or 
estradiol plus resveratrol all induced a significant increase of cell proliferation in 
RWPE-1 cells, that express all ERα and ERβ isoforms, except ERβ5 and in 
LNCaP cells that express all ERα and ERβ isoforms, except ERα66. In these 
two cell lines, resveratrol alone stimulated, while genistein and genistein plus 
resveratrol reduced prostate cell growth. Conversely, all treatment inhibited cell 
proliferation in androgen-resistant PC-3 cells that express only ERα36 and all 
ERβ splice variants. 
Steroid hormones play a significant role in growth and function of the normal 
prostate as well as in the development of BPH. Although serum estrogen levels 
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are low in healthy men [200], intraprostatic E2 levels increase in men with age 
and this increase is accompanied by the rise in the prostate volume [201,202]. 
Estrogens are synthesized from androgens through the aromatase enzyme and, 
therefore, an increased expression/activity of aromatase disrupts the balance of 
estrogen/androgen in the prostate. Many studies have detected aromatase 
expression and function in human prostate respectively using RT-PCR and 
biochemical assay of potential enzyme activity [26,43,47]. Estrogen levels in the 
stromal compartment of BPH increases with age [24] and this increase has 
been associated with an elevated expression of aromatase in prostatic stromal 
cells, especially around hyperplastic glands of BPH patients [199]. Recent 
studies have reported that PGE2 up-regulates aromatase expression in breast 
cancer [203], endometriosis and uterine leiomyomata [204]. COX-2 is a key 
enzyme in PGE2 biosyntheses. In this work, using RT-PCR, an E2-inducible 
COX-2 expression was observed in RWPE-1 and PC3 cells, while no COX-2 
could be detected in LNCaP cells. Aromatase expression was very low or 
undetectable in all cell lines tested (RWPE-1, LNCaP and PC-3 cell lines) and 
this evidence was confirmed by chromatographic analysis of Aro activity. 
Treatments with 1 nM E2 resulted in the up-regulation of Aro expression in Aro-
negative LNCaP and PC3 cells. Interestingly, PGE2 was also able to induce Aro 
expression in the two cell lines. In addition, the use of specific COX 1/2 inhibitor, 
SC-560 or NS-398, resulted in a decrease or in the abrogation of the E2-
induced Aro expression, suggesting that both COX1/2-dependent and 
independent effects of SC-560 and NS-398 could be implicated in the regulation 
of Aro expression in human prostate cancer cells. Furthermore, when androgen 
metabolism was investigated in separate epithelial and stromal cells from BPH, 
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aromatase activity was present only in stromal cells. It is conceivable that in the 
prostate of elderly men, characterized by an inflammatory environment, 
increased aromatase expression would eventually led to locally elevated 
estrogen that could in turn stimulate proliferative activity of prostate epithelial 
cells in a paracrine fashion.  
The assessment of androgen and estrogen metabolism revealed that distinct 
metabolic patterns of both estrogen and androgen are encountered in cultured 
nontumoral and malignant human prostate epithelial cells and that this different 
metabolic aptitude is reflected in the prevalence of reductive metabolism in 
nontumoral (RWPE-1) and cancer (LNCaP) androgen-responsive cells, while 
oxidative pathways are largely prevalent in neoplastic, androgen-refractory cells 
(PC3). Furthermore, different enzyme activities, including 17β-hydroxysteroid 
dehydrogenases (HSDs), sulfotransferase/sulfatase and glucuronil-transferase, 
appear to be significantly associated with steroid receptor status. In vivo studies 
conducted using exactly the same experimental conditions have revealed that 
both BPH and prostate cancer tissues exhibit a predominantly reductive 
androgen metabolism, eventually leading to the formation of large amounts of 
bioactive androgen derivatives (DHT, diols), though reductive metabolism was 
remarkably higher in cancer than in BPH tissues. However, results from primary 
cultures of stromal and epithelial cells separated from BPH tissues showed a 
dominant oxidative androgen metabolism, leading to the formation of 17keto 
androgen metabolites in both cell compartments. This combined evidence 
suggests that bioactive androgens are being actively produced in both BPH and 
prostate cancer tissues and that stromal-epithelial interaction appears to be 
crucial in determining the ultimate androgen metabolic pathways.  
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In summary, this study indicates that human nonmalignant prostate epithelial 
cells express exclusively wild-type ERα66 and that, hence, estrogen are likely to 
regulate growth and function of these target cells via a receptor-mediated 
signaling. On the contrary, prostate cancer cells exhibit a variable pattern of ER 
expression and, therefore, their response to estrogen or antiestrogen depends 
upon the differential expression of individual ER subtype(s). Overall, data from 
this study support to the conception that ER splice variant may play a central 
role in estrogen/antiestrogen signaling in normal and malignant human prostate. 
In addition, the evidence presented herein suggests that, in an inflammatory 
environment, prostate epithelial cells may potentially induce stromal aromatase  
through the secretion of PGE2 and aromatase overexpression could in turn lead 
to locally elevated E2. This latter, on one hand, induces directly COX-2, which 
produces high concentrations of PGE2, generating a vicious-circle. On the other 
hand E2 increases AREG synthesis/shedding, creating a rapid, nongenomic 
mechanism that ultimately leads to stimulate cell proliferation through activation 
of EGFR signaling. This mechanism could be triggered by either ligand-
dependent or –independent stimuli (figure 22). 
 
Figure 22. Estrogen signaling mechanisms in human prostate. Modified from Gail P Risbridger et 
al 2007. 
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6. CONCLUSIONS 
In spite of the recent, significant advances in the research on prostate cancer, 
mechanisms underpinning development and progression of the malignant 
prostate remain undefined. Several networked factors, including the balance of 
estrogen and androgen, changes and polymorphisms in the enzymes 
responsible for the biosynthesis and transformation of intraprostatic hormones, 
alteration of hormone signaling or local balance between estrogen receptor 
types and variants, may all be markedly affected by lifestyle factors (notably 
diet), genetic determinant and exposure to environmental chemicals. Presently, 
the lasting conception that androgens are the key determinants in prostate 
carcinogenesis and tumor progression appears to be a never-ending 
persuasion that has, faultily led to neglect different areas of research with 
promising perspectives for both treatment and prevention of this disease. In 
particular, steroid enzyme inhibitors [205], as well as ER subtype selective 
agonists/antagonists or SERMs [206,207], have been in turn proposed as 
potential agents for both chemoprevention and treatment of prostate cancer. In 
a review, Williams [208] proposes that several distinct factors may significantly 
affect hormone balance in the organism, including up-regulation of the P450 
aromatase enzyme and the resulting unopposed excess of endogenous 
estrogen, alteration of insulin receptor machinery and leptins, exposure to 
elevated environmental xenoestrogens. This unbalanced hormonal milieu may 
represent a common condition for development of life-threatening diseases, 
including, diabetes, obesity, Alzheimer’s disease and many type of cancer 
including prostate. 
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The evidence presented in this work strongly supports the concept that, likewise 
for breast cancer, changes in aromatase expression and/or activity can be 
important for development and/or progression of human prostatic carcinoma 
and that locally elevated estrogen may have a significant impact on the 
proliferative and functional regulation of prostate cells also through rapid 
(nongenomic) signaling mechanisms. In this respect, a better knowledge and 
understanding of estrogen-driven mechanisms in different processes related to 
human health and disease would be of primary importance to design and exploit 
original preventive and therapeutic strategies also in prostatic carcinoma.  
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